經(jīng)銷協(xié)議以下簡稱本由雙方于年月日在簽署生效

經(jīng)銷協(xié)Distribution ]日在簽署生效：ThisDistributionAgreement(hereinafterreferredtoasthis“Agreement”)ismadeandenteredintobyandbetweenthefollowingpartieson[ ],inShanghai:愛的發(fā)制藥，一家根據(jù) （以下簡稱“中國”）法律成并存續(xù)的公司，地址位于 市青浦區(qū)318國道16號橋南首前云路278號（以下簡稱“甲方”）；ShanghaiEthypharmCo.,.,alimitedliabilitycompanyestablishedandexistingunderthelawsofPeople’sRepublicofChina(hereinafterreferredtoas“China”,“Chinese”or“PRC”),witharegisteredaddressat278QianYunRoad,SouthofBridge16,NationalHighway318,XuJing,QingpuDistrict,Shanghai(hereinafterreferredtoas“PartyA”). ]，一家根據(jù)中國法律成立并存續(xù)的公司，地址位于 （以下簡稱“乙方”） ],alimitedliabilityestablishedandexistingunderthelawsofPRC,witharegisteredaddressat (hereinafterreferredtoasthe“Party本協(xié)議中，甲方和乙方單稱為“一方”，合稱為InthisAgreement,PartyAandPartyBarereferredtoindividuallyasa“Party”andtogetherasthe“Parties”.鑒于PartyAisapharmaceuticalmanufacturingcompanywithlegalqualificationsandagoodreputationandPartyBisapharmaceuticalsalescompanywithlegalqualificationsandagoodreputation.PartyAdesirestoappointPartyBasitsdistributorforthepharmaceuticalslistedin entIheretoandPartyBdesirestoaccepttheaforesaidappointment.為進一步明確雙方的權利和義務，現(xiàn)根據(jù)《中民合同法》等相關的規(guī)TofurtherclarifybothParties’rightsandobligations,thefollowingagreementisherebyreachedinaccordancewiththePRCContractlawandotherrelevantlawsandregulations:甲方特此乙方，非獨家經(jīng)銷商，向本協(xié)議附件一所列城市內(nèi)的醫(yī)院（以下簡稱“區(qū)域”）銷售附件一中所列明的藥品（以下簡稱“藥品”）。PartyAherebyauthorizesPartyB,asnon-exclusivedistributorofPartyA,tosellthepharmaceuticalslistedintheAttaentI(hereinafterreferredtoasthe“AuthorizedPharmaceuticals”)totheauthorizedhospitals(hereinafterreferredtoasthe“Territory”)whicharelocatedintheauthorizedcitieslistedintheAttaenthereof.Unlessotherwiseprovidedherein,PartyBshallnotpurchasecommoditieswhicharethesameasorsimilartotheAuthorizedPharmaceuticalsfromanythirdpartyotherthanPartyAorpromotethesamewithintheTerritory.NeithershallPartyB eadistributororanagencyofanythirdpartywhiaycompetewithPartyA.經(jīng)甲方另行同意，乙方可代表甲方參與有關藥品的投標活動。乙方明確，即使乙方投標失敗，甲方亦無需就藥品向乙方支付任何補償或承擔任何責任，但本協(xié)議另有約定或法SubjecttoawrittenconsentgivenbyPartyAseparay,PartyBmay,onbehalfofPartyA,engageinanybiddingactivityrelatedtotheAuthorizedPharmaceuticals.PartyBconfirmsthat,PartyAhasnoobligationtomakeanycompensationtoorundertakeanyliabilityagainstPartyBwithregardtotheAuthorizedPharmaceuticalsevenifPartyBfailstowinthebidding,unlessotherwiseagreedhereinorforcedbylaws.為提升物流能力，經(jīng)甲方事先同意，乙方可指定有資質(zhì)的、信譽良好的且經(jīng)甲方認可的第配送藥品。乙方明確，該等指定不應免除乙方履行本協(xié)議項下的義務，包括支付本協(xié)議第2.4條所規(guī)定的保證金。Toincreaselogisticscapabilities,uponPartyA’spriorwrittenconsent,PartyBmayappointqualified,reputablethirdpartyacceptedbyPartyAtodelivertheAuthorizedPharmaceuticals.PartyBconfirmsthat,suchappointmentshallnotrelievePartyBfromfulfillingitsobligationshereunder,includingtopaythedepositsetforthinArticle2.4.訂單、價格和付款方Order,Priceand訂WhenorderingtheAuthorizedPharmaceuticals,PartyBshallsubmitawrittenordertoPartyA,underwhichthefollowinginformationshallbeatleastspecified(hereinafterreferredtoasthe“Order”):訂購藥品的藥品通用名、商品名、劑型和規(guī)格thePharmaceuticalsGenericName,CommodityName,DosageFormandSpecificationoftheorderedAuthorizedPharmaceuticals;配送日期，該日期不應早于訂單提交日期后的 ]日deliverydate,whichshallnotbeearlierthan[ ]daysafterthesubmissionofanorder;送貨地址及簽收人和deliveryaddressandthenameandcontactsof dIfPartyAfailstoperformthisAgreementorsuffersanylossduetothemistakesinanyorder,PartyBhasnorighttoclaimindemnificationagainstPartyAandifnecessary,PartyAhastherighttodemandanindemnificationfromPartyB.Order乙方除了藥品的第一筆訂單應至少提前[]個月下訂單，其余應至少提前[]個月下訂單（“交貨周期”）。在[]個工作日內(nèi)，甲方應確認每一訂單的接收日期，并將其作為交貨周期的開始日期（“接受日期”）。藥品應在交貨周期內(nèi)發(fā)貨，除非甲方根據(jù)如下條款另行作出確認。PartyBshallplaceitsordersatleast[]monthsinadvance(eacha“LeadTime”)exceptforthefirstorderofAuthorizedPharmaceuticalsthatshouldbeorderatleast[]monthsinadvance.Nolaterthan[]workingdays,PartyAshallconfirminwritingdateofreceptionofeachorderwhichshallbeconsideredasthedateofthestartoftheLeadTime(“DateofReceipt”).AuthorizedPharmaceuticalsshallbedeliveredwithintheLeadtimeunlessotherwiseconfirmedinwritingbyPartyApursuanttothetermsbelow.一旦甲方確認接受，此訂單將視為一個實盤且不可撤銷的、對雙方產(chǎn)生約束力的訂單。若在接受日期后的[個月內(nèi)，沒有接到甲方的任何進一步溝通，則應視為已接受相關的訂單且藥品的發(fā)貨日期應于上面提及的交貨周期內(nèi)作出。TheordersshallbeconsideredasfirmandirrevocableandshallbindbothPartiesassoonasacceptedinwritingbyPartyA.IntheabsenceofanyfurthercommunicationfromPartyA[]monthaftertheDateofReceipt,therelevantordershallbeconsideredasacceptedanddeliverydateoftheAuthorizedPharmaceuticalsshallbemadewithintheLeadTimesassetforthabove.PurchasePriceand訂購藥品的總購銷價格（以下簡稱“購銷價款”）均應以訂單中所載明的數(shù)量及本協(xié)議附件一所列的單價（以下稱“單價”）為準。甲方確認接受訂單后的[]天內(nèi)，乙方應以銀行轉(zhuǎn)賬的方式向甲方支付購銷價款100%。ThetotalpurchasepriceoftheAuthorizedPharmaceuticals(hereinafterreferredtoasthe“PurchasePrice”)shallbesubjecttothetiesspecifiedinanorderandtheunitpricelistedinAttaentI(hereinafterreferredtoasthe“UnitPrice”).Within[]daysuponPartyAacceptstheorder,PartyBshallpay100%ofthePurchasePricetoPartyAbybanktransfer.WhenPartyAagreesPartyBtoengageinanybiddingactivities,ifthebid-winningpriceoftheAuthorizedPharmaceuticalsislowerthantheUnitPrice,PartyBhasarighttorequestPartyAtoadjusttheUnitPrice,andtheadjustmentrangeshallbenegotiatedbetweentheParties.保證自本協(xié)議簽署之日起[個工作日內(nèi)且在乙方向甲方遞交本協(xié)議項下第一筆訂單前，乙方應當向甲方支付[]萬元，作為醫(yī)院推廣保證金。前述保證金將于本協(xié)議到期或終止時或甲方藥品投標失敗時予以返還，但乙方在本協(xié)議期間存在如下任Within[]workingdaysupontheexecutionofthisAgreementandbeforethefirstOrdersubmittedbyPartyBtoPartyA,PartyBshallpayRMB[ ]toPartyAasahospitalpromotiondeposit.SuchdepositwillberefundedwhenthisAgreementexpiresorterminatesorwhenPartyAlosesanybiddingfortheAuthorizedPharmaceuticals,exceptthatPartyBhasanyofthefollowingbehaviorsduringtheTermofthisAgreement:推廣期間擾亂市場（例如亂價、竄貨disturbthemarketduringthepromotionperiod(e.g.disorderlyprice,sellingtheproductoutoftheTerritory);crosssalesorpliancewithPartyA’ssalesorprice變更藥品的內(nèi)外包裝changeofinsideoroutsidepackagingoftheAuthorized未能遵守本協(xié)議第7.3pliancewiththeundertakingofpurchasesvolumesetforthinArticle7.3herein;甲方認為屬于嚴重本協(xié)議的其他情形othercircumstancesPartyAdeemsasasignificantbreachofthisIncasethecircumstancesetforthinArticle2.4(1)occurs,PartyAhastherighttoforfeitsuchdepositandterminatethisAgreementimmediaywithoutnotice.在如上第(5)種情形中，藥品在區(qū)域內(nèi)一年的采購量如低于該年相應最低年采購量的50%，則甲方?jīng)]收該筆保證金并提前[]個月通知終止本協(xié)議。InthecircumstancesetforthinArticle2.4(5),ifthevolumesofpurchasesoftheAuthorizedPharmaceuticalsintheTerritoryforonegivenYear,are50%belowtherelevantMinimumAnnualpurchasesinsaidYear,PartyAhastherighttoforfeitsuchdepositandterminatethisAgreementwitha[]monthpriorwrittennotice.發(fā)生如上第(2),(3),(4),(6)種情形的，甲方亦沒收該筆保證金PartyAhastherighttoforfeitsuchdepositincasethecircumstancesetforthinArticle2.4(2),(3),(4)or(6)occurs.若甲方按照本協(xié)議約定沒收全部或部分保證金，乙方應當在30日內(nèi)予以補足。若乙方未補足保證金，甚至在甲方通知后仍不糾正，則甲方立即解除本協(xié)IfPartyAforfeitsallorpartofthedepositunderthisAgreement,PartyBshallmakeupthesumofthedepositwithin30days.IfPartyBfailstomakeupthesumtimely,andevenfailstofulfillitsobligationuponreceiptofthePartyA’notice,PartyAwillbeentitledtoterminatetheAgreementimmediay.配送和驗Delivery,Inspectionand配甲方應當按照訂單要求向乙方配送藥品PartyAshalldelivertheAuthorizedPharmaceuticalstoPartyBinaccordancewiththeorder.Beforedelivery,PartyAshallnotifyPartyBinwritingsothatPartyBmayarrangeforinspectionandacceptance.Whendelivering,PartyAshallcollaterallyprovidethepharmaceuticalsinspectionreportsoftheAuthorizedPharmaceuticalswiththesamebatchnumberandtherelevantentrustagreements(ifapplicable).IfPartyAfailstodelivertheAuthorizedPharmaceuticalsonschedulebecauseofthereasonsunattributabletobothParties,PartyAshalltimelynotifyPartyBofitsdelayofperformanceandthereasonsthereofinwriting.ThePartiesshallinitiateanegotiationtoseekasolutionacceptabletobothParties.驗Inspectionand藥品到達配送地點后，乙方應立即組織驗收，并當場簽署驗收單。乙方不得無故或拖延簽收。自簽署驗收單之日起，乙方享有實際配送的藥品的所并需AftertheAuthorizedPharmaceuticalsarrivedattheplaceofdelivery,PartyBshallimmediayarrangeforinspectionandacceptance,andthereaftersignthedeliveryreceiptonthespot.PartyBshallnotfornoreasonrejectordelaytosignthedeliveryreceipt.Asoftheexecutionofthedeliveryreceipt,theactualdeliveredAuthorizedPharmaceuticalsaretitledtoPartyBandPartyBshallbearalltherisks檢驗時，如發(fā)現(xiàn)實際配送的藥品與訂單不一致，乙方應立即通知甲方予以補充、更換或運回。在甲方前往配送地點取回或更換藥品前，乙方應自費妥善保管Wheninspecting,iftheactualdeliveredAuthorizedPharmaceuticalsarefoundtobeinconsistencewiththeonesundertheOrder,PartyBshallpromptlyinformPartyAtosupplement,replaceorwithdraw.BeforePartyAwithdrawsorreplacestheAuthorizedPharmaceuticalsfromtheplaceofdelivery,PartyBshalldulykeeptheAuthorizedPharmaceuticalsfromfurtherdamagesatitsowncost.因乙方導致甲方未能履行上述義務的，甲方不承擔任何責任PartyAbearsnoliabilitiesforitsfailuretoperformtheaboveobligationsifsuchfailurecanbeattributabletoPartyB.所轉(zhuǎn)Transferof藥品的所自乙方按照本協(xié)議第3.2條的規(guī)定簽署驗收單后方才轉(zhuǎn)移至乙方。TheownershipoftheAuthorizedPharmaceuticalsshallbetransferredtoPartyBonlyafterPartyBhassignedthedeliveryreceiptinaccordancewithArticle3.2.質(zhì)量標QualityUndertakingsof藥品安全等有關的規(guī)定。PartyAundertakestoprovidePartyBtheAuthorizedPharmaceuticalsinaccordancewiththeattaentsofthisAgreement,whicharefullycompliancewiththeprovisionsofChinesepharmaceuticalsafetylawsandregulations.質(zhì)量瑕疵或缺FlawsorDefectsin如果乙方發(fā)現(xiàn)藥品因在使用中出現(xiàn)任何瑕疵或缺陷而不符合質(zhì)量標準，乙方應在發(fā)現(xiàn)該瑕疵或缺陷后的1個月內(nèi)向甲方提出通知，并同時將有關的樣品寄回給甲方以受其。IftheAuthorizedPharmaceuticalsisfoundbyPartyBnottocomplywiththequalitystandardduetoanyflawordefectappearinginthecourseofuse,PartyBshallnotifyPartyAinwritingwithinonemonthafterthedetectionofsuchflawordefectandshallsimultaneouslysendtoPartyAthesamplesconcernedfor將有瑕疵、缺陷的藥品進行，相應的費用由甲方承擔。Intheeventthatuponexaminationandinspection,PartyAdemonstratethenoncomplianceoftheAuthorizedPharmaceuticalswiththequalitystandard,PartyAmayrequestPartyBtorecallthedefectiveorflawedAuthorizedPharmaceuticalsatPartyA’scostsinaccordancewiththeapplicablelawsandregulationsinthe無論何時，乙方一旦察覺到藥品出現(xiàn)任何的瑕疵或缺陷，應向甲方報告這些瑕疵動，例如，停止經(jīng)銷并通知相關第）。WheneverPartyBshall eawareofanyflawedordefectiveAuthorizedPharmaceuticals,PartyBshallreportanysuchdefectsorflawstoPartyAandmakeallreasonablecommercialeffortstomitigaterisks,costsandpotentialliabilitiesassociatedtherewith(takingsuchstepsas,forinstance,discontinuingdistributionandnotifyingrelevantthirdparties).質(zhì)量瑕疵或缺陷的ConsequencesofFlawsandDefectsin乙方要求PartyBhastherightto對有瑕疵或缺陷的藥品進行退、換貨，費用由甲方承擔，areplacementoftheflawedordefectiveAuthorizedPharmaceuticalsatPartyA'costs,or在乙方提出要求的30日內(nèi)，對有瑕疵或缺陷的藥品給與退款。arefundfortheflawedordefectiveAuthorizedPharmaceuticalswithin30daysuponPartyB’writtenrequest.如果雙方在藥品是否符合質(zhì)量標準的認定上存在異議，雙方同意將問題藥品提交一家由雙方共同選擇的獨立機構進行檢測。重新檢測的結果對雙方均有約束力，過錯IncaseofdisagreementbetweenthePartiesastothecomplianceoftheAuthorizedPharmaceuticalswiththequalitystandard,thePartiesagreetosubmitthepharmaceuticalsinquestiontoanindependentexpertchosenbythePartiesjointlyfortesting.TheresultsofsuchretestingwillbebindingonthePartiesandthePartyfoundindefaultwillbearthecostsofretesting.PartyBacknowledgesthat,PartyAbearsnoliabilitiesfortheexpiry,ineffectivenessorthequalityreductionoftheAuthorizedPharmaceuticalswhichareattributabletoPartyB(includingimproperuseorkee,包裝標Packing方在訂單中特殊包裝要求而產(chǎn)生的附加費用，應由乙方另行支付。UnlessotherwiserequestedbyPartyBinanorder,PartyAshall,accordingtothebusinesspractices,deliver,storeandpackagetheorderedAuthorizedPharmaceuticals.PartyBshallbeartheadditionalexpensesincurredfromthespecialpackagingrequirementsitproposedinsuchorderseparay.包裝要求變更，一方應立即通知另一方，以尋求一個雙方均可接受的包裝方式。為免疑義，雙方應就此另行簽署一份文件。Incaseofchangeofpackagingrequirements,onePartyshallpromptlynotifytheotherPartytoseekforapackingmanneracceptabletobothParties.Toavoiddoubts,thePartiesshallseparayexecuteawritten 推Promotion乙方應自負費用在區(qū)域內(nèi)盡力推廣銷售藥品。乙方應以合法的方式，按照授銷活動。乙方承諾將在每日年初的[]個月內(nèi)，向甲方遞交在區(qū)域內(nèi)推廣和銷藥品的市場計劃以及相關的PartyBshalluseitsdiligenteffortstomarketandselltheAuthorizedPharmaceuticalswithintheTerritoryatitsownexpense.PartyBshallconductitsmarketingactivitiesinalawfulmannerwithappropriateorapplicablestandardsofpharmaceuticalproductpromotionalpractices,fairtrade,faircompetition,andbusinessethics.PartyBundertakestosubmittoPartyAwithin[]monthsfromthebeginningofeachcalendaryear,aproposedmarketingplanwithrelevantbudgettopromoteandmarkettheAuthorizedPharmaceuticalsintheTerritory.推Promotion乙方將使用所有必要及適當?shù)囊栽趨^(qū)域內(nèi)成功銷售并推廣該藥品。那些推廣研討會，在相關醫(yī)學雜志上登等。乙方應對其員工進行適當?shù)呐嘤?，或可PartyBwilluseallnecessaryandadequatemarketingtoolstosuccessfullypromoteandselltheAuthorizedPharmaceuticalsintheTerritory.Thosemarketingtoolsare,butnotlimitedto:allnecessaryprintmaterial,participationonrelevanttradeshows,conferences,exhibitionsandpromotionalseminars,advertisinginrelevantmedicalmagazinesetc.PartyBshalltrainmembersofitsstaff,asappropriate,orhireandtrainadditionalstaff,soastobeabletocarryoutPartyB'sobligationsunderthis敗Anti-乙方承諾將采取所有合理可行的措施和程序以確保其推廣行為符合全部，特別是有關敗的規(guī)定。若乙方被發(fā)現(xiàn)在推廣中有任何行為，甲方立即以書PartyBundertakesthatitwilladoptallreasonableandpracticablepoliciesandprocedurestoensureitspromotionscompliancewithalllawsandregulations,particularlytheanti-corruptionrules.IfPartyBisbeofferinganybribesanybribeinpromotions,PartyAisentitledtoterminatethisagreementimmediaywithawrittennoticetoPartyBandrequestPartyBtoundertakeliabilitiesofbreachunderthisAgreement.銷售預測與采購量保ForecastsandUndertakingofPurchases乙方應向甲方提供藥品在區(qū)域內(nèi)銷售的[]個月滾動的銷售預測，每一季度更新PartyBshallprovidePartyAwitha[]monthsrollingforecastoftheAuthorizedPharmaceuticalstobesoldontheTerritory,updatedeveryquarter.ThesaidestimatedannualrequirementshallbecommunicatedbyPartyBforinformationpurposesandshallnotconstituteafirmcommitmentbybothParties.超出乙方年度銷售預測中相關部分數(shù)量的[]%并且甲方在至少在發(fā)貨日期前的[]個PartyAshallacceptanddeliveralltheordersplacedbyPartyBinaccordancewiththeestimatedannualrequirementcommunicatedbyPartyBprovidedthatthetiesordereddonotvarybymorethan[]%fromthetiesindicatedintherelevantpartofPartyB’sannualforecastandprovidedthatPartyAreceivestheorderaminimumof[]monthsbeforethedeliverydate.庫乙方應始終保持足夠的藥品庫存以滿足區(qū)域內(nèi)市場的需求。這些庫存應該足以滿足至少3個月的預計需求。PartyBshallatalltimes,keepadequateinventoriesofAuthorizedPharmaceuticalstomeetthemarketdemandintheTerritory.Theseinventoriesshallbesufficienttocovertheestimatedrequirementforatleast3months.采購量保UndertakingofPurchases乙方承諾自本協(xié)議簽署之日起的每一個年度，在區(qū)域內(nèi)達到附件二中所述年最低采購量（“最低年采購量”），該最低年采購量應由雙方在每個年度終了前重新審閱并通過PartyBundertakestoreachintheTerritoryminimumannualsalesrequirementssetforthintheAttaentIIforeachyearperiodfollowingthedateofexecutionoftheAgreement(the“MinimumAnnualPurchases”).SuchminimumannualPurchasesrequirementshallbereviewedandadjustedbybothPartiesbysigningmemorandumbeforeexpirationofeachyearperiod.責任和義Responsibilitiesand甲方應當PartyA按照本協(xié)議及其附件的規(guī)定配送藥品delivertheAuthorizedPharmaceuticalsinaccordancewiththisAgreementanditsattaents.件。因甲方未及時提供投標文件而導致投標失敗的，乙方可就其所的損IncasePartyAagreesPartyBtoengageinanybiddingactivity,PartyAshallpromptlyprovidecorrespondingbiddingstoPartyB.PartyBhasarighttoclaimanindemnificationagainstPartyAforthelossessufferedfromthefailureofbiddingduetoPartyA’sfailureinprovidingthebiddingstimely.乙方應當PartyB按照本協(xié)議條款和條件采購藥品。除甲方發(fā)生重大違約行為且經(jīng)乙方通知后未能在合理時間內(nèi)予以糾正外，乙方不得擅自向第采購藥品。purchasetheAuthorizedPharmaceuticalsinaccordancewiththetermsandconditionsofthisAgreement.UnlessPartyAmateriallybreachestheAgreementanduponPartyB’snotice,itfailstorectifysuchbreachwithinareasonableperiod,PartyBshallnotarbitrarilypurchasetheAuthorizedPharmaceuticalsfromanythirdparty.在參與藥品的投標活動過程中，僅出于投標目的合法地使用甲方所提供whenengaginginthebiddingactivitiesrelatedtotheAuthorizedPharmaceuticals,legallyuseanybidding orinformationthatPartyAprovidedforbiddingpurposeonly.reportthebiddingprocessandresultstoPartyAfromtimetotimeandobeytheinstructionandfinaldecisionofPartyA.及時向甲方通報區(qū)域內(nèi)藥品的各種不良反應和突發(fā)事件，并協(xié)助甲方處informPartyAalltheside-effectsandsuddencasesrelatedtotheAuthorizedPharmaceuticalswithintheTerritoryinatimelymanner,andassistPartyAtodealwithsuchproblems.遵守甲方制定的行為準則、銷售政策和價格體系，在甲方事先允許的情況下，不得以低于單價的價格銷售藥品，不得以甲方行為準則或銷售政策的方式銷售、推廣藥品。因乙方原因?qū)е聟^(qū)域內(nèi)市場紊亂的，乙complywithPartyA’scodeofconduct,salespoliciesandpricesystem.WithoutthepriorapprovalofPartyA,PartyBshallnotselltheAuthorizedPharmaceuticalsatthepricelowerthantheUnitPriceandshallnotpromoteorselltheAuthorizedPharmaceuticalsinsuchamannerviolatingPartyA’scodeofconductorsalespolicies.PartyBshallbearallliabilitiesforthemarketdisordersitcausedwithintheTerritory.就甲方為本協(xié)議之目的而向其披露的任何屬于甲方的信息予以keepanyinformationbelongingtoPartyAanddisclosedbyPartyAforthepurposeofthisAgreementin.于每月第5個工作日前向甲方遞交包含有、開票日期、醫(yī)院名稱、submitamonthlysalesreporttoPartyAbeforethefifthworkingdayofeachmonth,whichshallcontain date,hospitalnames,thetitle,dosage,specification,tyoftheAuthorizedPharmaceuticals,etc.于每月第5個工作日前向甲方遞交包含有批次號、藥品名稱、劑型、規(guī)submitamonthlyinventoryreporttoPartyAbeforethefifthworkingdayofeaonth,whichcontainsbatchnumber,thetitle,dosage,specification,tyoftheAuthorizedPharmaceuticals,etc.保雙方應在本協(xié)議期限內(nèi)自負費用地向信譽良好的保險公司投以適當?shù)漠a(chǎn)品責任保險，保單項下印件及續(xù)費收據(jù)的復印件。EachPartyshallatitsownexpensemaintainwithareputableinsurancecompanyduringtheTermofthisAgreementadequateproductliabilityinsurancepoliciesissuedinsuchcoverageamountsasiscustomaryforsuchParty’sbusinessandconsistentwithindustrystandards.EachPartyshallupontherequestoftheotherPartyproduceacopyofanyrelevantinsurancepolicytogetherwithacopyofthelatestrenewalreceipt.知 lectual甲方保證，其向乙方出售的藥品不任何第的知識，且乙方對藥品的銷售亦不會導致任何第向其提出任何有關于藥品知識或其他方面的或主張。PartyAundertakesthat,theAuthorizedPharmaceuticalsitsellstoPartyBdonotinfringeanythirdparty’sinlectualpropertyrights,andPartyB’ssaleoftheAuthorizedPharmaceuticalswillnotentitleanythirdpartytobringanylawsuitormakeanyclaimagainstPartyBfortheinlectualpropertyorotheraspectsoftheAuthorizedPharmaceuticals.乙方保證僅出于本協(xié)議之目的，經(jīng)甲方另行同意后，合法使用藥品的任何知PartyBundertakestolegallyuseanyinlectualpropertyoftheAuthorizedPharmaceuticalsuponaseparaywrittenconsentofPartyAandforthepurposeofthisAgreementonly.乙方確認，甲方擁有在區(qū)域內(nèi)、銷售和推廣的藥品的商標（以下簡稱“商標”）、材料和規(guī)范性文件之上的任何及所有知識的完整權利。乙方應僅為甲方的利益而使用該等商標、材料和規(guī)范性文件，任何因乙方使用該等授權商標、材料和規(guī)范性文件而累積的商譽和聲譽應歸于甲方。PartyBacknowledgesthat,PartyAretainsfullownershipofallandanyinlectualpropertyrightsrelatingtothetrademarks(hereinafterreferredtoasthe“AuthorizedTrademark”),marketingmaterialsandregulatorysinrespectofthemarketing,saleandpromotionoftheAuthorizedPharmaceuticalsintheTerritory.PartyBshallusesuchAuthorizedTrademark,marketingmaterialsandregulatorysforthesoleandexclusivebenefitofPartyAandanygoodwillandreputationaccruedinconnectionwithPartyB'suseofsuchAuthorizedTrademark,marketingmaterialsandregulatorysshallaccruetoPartyA.乙方不得且應促使其任何關聯(lián)方不得PartyBshallnot,andshallprocurethatanyofitsaffiliatesdo使用與某一藥品商標相同、相或類似的任何其他標記或名稱，而該等藥品與藥品存在競爭關系、或與之類似或與藥品具有相同指示；useanyothermarkornamethesameasorconfusinglysimilartothetrademarkinrelationtoapharmaceuticalproductwhichiscompetitivewith,similarto,orindicatedforthesameindicationsastheAuthorized在世界各地與某一藥品商標相同或相或類似的任何標記或獲取該等標記的，而該等藥品與藥品存在競爭關系、或與之類似或與藥register,orprocuretheregistrationof,anymarkthesameasorconfusinglysimilartothetrademarkforapharmaceuticalproductwhichiscompetitivewith,similarto,orindicatedforthesameindicationsastheAuthorizedPharmaceuticalsanywhereintheworld;的外，乙方或其任何關聯(lián)方或有擁有或使用商標。除本協(xié)議有明確外，乙方不得且應促使其任何關聯(lián)方不得就商標主張任何權利或以其他方式給予使用商標的；makeanymaterialrepresentationordoanymaterialactwhichmaybetakentoindicatethatithasanyright,titleorinterestinortotheownershiporuseoftheAuthorizedTrademarkotherthanasconferredbythisAgreement.PartyBshallnotandprocurethatanyofitsaffiliatesdonotclaimanyrightintheAuthorizedTrademarkorotherwisegivepermissiontousethesameexceptasexpresslygrantedinthisAgreement;或協(xié)助任何人甲方的知識challengePartyA’sright,orassistanyoneinachallengetoPartyA’sright,tosuchinlectualpropertyrights;如發(fā)現(xiàn)任何關于商標的、潛在的或行為或任何人提出了授權商標無效或的任何主張或，乙方或其任何關聯(lián)方應在合理且可行的時間內(nèi)盡快通知甲方，甲方事先同意，不得就該等事項作出任何informPartyAassoonasreasonablypracticableifPartyBoranyofits esawareofanyinfringement,threatenedinfringementorpassingoff,oranyclaimorallegationbyany ofinvalidityorinfringementinrespectoftheAuthorizedTrademarkandnoneofthemshallmakeanyadmissionorcommentinrelationtosuchmatterswithoutthepriorwrittenconsentofPartyA.期本協(xié)議有效期為[]年，自[年[]月[]日起至[年[]月[]日止。期滿前[]個月，雙方未就續(xù)約提出異議的，本協(xié)議自動續(xù)展1年，除雙方另有約定或中國另有ThevalidtermofthisAgreementis[]years,commencingfrom[ ]andendedon[ ].IfthePartiesdonotraiseanobjectiontotherenewalofthisAgreementwithin[]monthspriortotheexpiry,thisAgreementshallbeautomaticallyrenewedforoneyear.UnlessotherwiseagreedbetweenthePartiesorprovidedbyChineselawsorregulations,thetermsandconditionsofthisAgreementshallremainunchangedwithintherenewal.違約和終Breachand違Breachof若甲方本協(xié)議第4條之規(guī)定，乙方除要求甲方退、換貨外，還要求甲方賠償。除法律另有規(guī)定外，賠償額度應以本協(xié)議第9條下甲IfPartyAbreachesArticle4,excepttorequestforthereplacementorreturnoftheAuthorizedPharmaceuticals,PartyBisalsoentitledtodemandanindemnificationfromPartyA.Unlessotherwiseprovidedbylaws,suchindemnificationshallbelimitedtoPartyA’spolicylimitsassetforthinArticle9.IfsuchpolicylimitsexceedtheamountofthePurchasePrice,suchindemnificationshallbelimitedtothePurchasePrice.乙方若未能按照本協(xié)議之規(guī)定向甲方支付購銷價款，則每遲延一日，乙方應按照未付款項的[]%向甲方支付違約金，直至購銷價款得以全部支付為止。IfPartyBfailstopayPartyAthePurchasePriceinaccordancewiththisAgreementanditsattaentshereto,PartyBshallpayPartyAaliquidateddamageof[]%oftheunpaidamountforeachdayitdelays,untilthePurchasePricehasbeenfullypaid.除本協(xié)議另有約定外，任何一方因本協(xié)議項出的、保證及其他Unlessotherwiseagreedherein,anyPartywhoviolatesthedeclarations,undertakingsandotherobligationshereundershallbeartheliabilityforsuchbreachesandifthecounterPartysufferslossestherefrom,suchbreachingPartyshallindemnifythenon-breachingParty.Theindemnificationshallonlyincludealldirectlossesthenon-breachingParty任何一方因本協(xié)議而需支付的任何性質(zhì)的賠償費用均應以本協(xié)議第2條項下購銷價款為限，但有關另有規(guī)定的除外。Theindemnification,inwhatevernature,thateitherPartypaysforitsbreachofthisAgreementoritsattaentsshallbelimitedtothePurchasePricedefinedunderArticle2hereof,unlessotherwiseprovidedbylawsorregulations.終發(fā)生如下情形之一的，本協(xié)議終止ThisAgreementshallbeterminateduponanyofthefollowing雙方協(xié)商一致Uponmutual一方因自身原因本協(xié)議且自收到另一方通知后亦未能在合理時間內(nèi)予以糾正的，守約方通知違約方終止本協(xié)議；IncaseeitherPartybreachesthisAgreementforthereasonsattributabletoitselfanduponthereceiptofthewrittennoticefromtheotherParty,thebreachingPartyfailstorectifysuchbreacheswithinareasonableperiod,thenon-breachingPartyisentitledtonotifythebreachingPartyinwritingtoterminatethisAgreement;一方或進入程序時，另一方通知該方終止本協(xié)議IncaseeitherPartyisbankruptorentersintoliquidationprocedures,theotherPartyisentitledtonotifysuchPartyinwritingtoterminatethis一方按照本協(xié)議第11EitherPartyraisesanobjectiontotherenewalofthisAgreementpursuanttoArticle11hereof;在上一年度終了后雙方未能按照第7.3條確定下一年度年最低采購量的；BothPartiesfailtodeterminetheMinimalAnnualPurchasesforthenextyearperiodafterexpirationofthepreviousyearperiod;Othercircumstancessetforthinthis本協(xié)議的終止不應影響雙方終止前已產(chǎn)生的債權關系TheterminationofthisAgreementshallnotaffectthedebtsorcreditsincurred適用法律和爭議解ApplicableLawandDispute履行而產(chǎn)生或與本合同自身有關的任何爭議送交有管轄權的。AllaspectsofthisAgreementshallbeernedbyandinterpretedinaccordancewithPRClaws.ThePartiesshallirrevocablysubmitanydisputearisingfromtheperformanceof,orinconnectiontothisAgreementtoacompetentPeople’sCourt.其他規(guī)完整協(xié)議和附EntiretyandAttaThefollowingattaents,astheinseparablepartofthisAgreement,togetherwiththisAgreementconstituteallunderstandingsandanentireagreementofthepurchaseandsaleoftheAuthorizedPharmaceuticalshereunder.附件一A：藥 entI:AListoftheAuthorized附件一B:省和城 entIBListoftheAuthorizedProvincesand附件二：關于年最低采購量的備忘 entII:MemorandumonMinimumAnnual通本協(xié)議要求或的任何通知或其他信息，均須以形式親手送交、郵寄、傳真，或以雙方同意的其他通訊方式，送至一方指定的如下地址。任何根據(jù)本協(xié)議發(fā)出的通知或其他信息，如果親手送交，則在送交時被視作已經(jīng)送達，如果用其他方式發(fā)送，48小時后被視作已經(jīng)送達。AnynotificationorinformationasrequiredorpermittedbythisAgreementmustbeinwriting,andmaybedeliveredin ,bypost,fax,orothercommunicationmethodsasmutuallyagreedtothefollowingaddressdesignatedbyeitherParty.IfanynotificationorotherinformationissuedinaccordancewiththisAgreementisdeliveredin ,thenitshallberegardedashavingarrivedwhenitissubmittedtotheotherParty.Ifothermethodsofdeliveryareemployed,thenitshallberegardedashavingarrivedafter48hourscommencingfromthetimeofdeliveryor [市青浦區(qū)318國道16號橋南首前云路278號]PartyA [278QianYunRoad,SouthofBridge16,NationalHighway318,XuJing,QingpuDistrict, PostalCode:傳真 [+8621 [+8621 乙方地址： Party ] PostalCode: 傳真 一方應當將任何有關上述情況的變更以形式立即通知另一方EitherPartyshallpromptlynotifyanychangesofaboveinformationtotheotherPartyinwriting.修對本協(xié)議的任何變更、補充、修改應以形式達成，并經(jīng)雙方簽署后方才生效。Anyalteration,supplementaryoramendmenttothisAgreementshallbeconclud